Vanessa Marcelo, DPM
Foot & Ankle Surgery · Pharr, TXNPI 1568950640
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (39.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Southern Edge Orthopaedics, Inc. at 39.0% of the total. Reporting peaked in 2021 at $1,090 and has fallen 88.3% since, to $128 in 2022. That places this record below the midpoint for foot & ankle surgery clinicians in TX, where the typical reported total is $3,901.
Across 31 payments — averaging $74.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Southern Edge Orthopaedics, Inc.$895
- Treace Medical Concepts, Inc.$779
- Amniox Medical, Inc.$170
- Amgen$161
- Kerecis Limited$115
- Biotissue Holdings Inc.$104
- plus $75 from 2 others
What the payments were for
- Travel & lodging$63228%
- Food & beverage$77034%
- Education$89539%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Southern Edge Orthopaedics, Inc. | 1 | $895 |
| Treace Medical Concepts, Inc. | 6 | $779 |
| Amniox Medical, Inc. | 2 | $170 |
| Amgen | 17 | $161 |
| Kerecis Limited | 1 | $115 |
| Biotissue Holdings Inc. | 2 | $104 |
| KCI USA, Inc. | 1 | $59 |
| Linvatec Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,298 in reported general payments places this provider in the 35th percentile of 684 foot & ankle surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ciclopirox | 531 | $19,650 |
| Naftifine Hcl | 33 | $10,592 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 100 | $2,177 |
| Ammonium Lactate | 36 | $835 |
| Diclofenac Sodium | 29 | $787 |
| Cephalexin | 63 | $388 |
| Mupirocin | 19 | $237 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $221 |
| Clindamycin Hcl | 17 | $184 |
| Ciprofloxacin Hcl | 15 | $153 |
| Doxycycline Hyclate | 11 | $91 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Pharr
- William McGarveyKaty$3.5M
- Eugene CurryDallas$3.1M
- Graham HamiltonEdinburg$2.1M
- Mark DaltonAustin$1.9M
- Kevin VarnerHouston$1.1M
- Paul KimDallas$928K
- Sherman NaglerHouston$602K
- John EarlyDallas$553K
- Michael DowneySouthlake$475K
- Abdul NurudeenHouston$404K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.